Konrad Zieliński

Konrad Zieliński

Auto-generated profile, based on publicly available information

Konrad Zieliński

Pomeranian Medical University, Szczecin, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PBPaweł Buć
Paweł Buć
JJJagoda Józefczyk
Jagoda Józefczyk
KBKarolina Buć
Karolina Buć
ŁKŁukasz Krzystek
Łukasz Krzystek
KZKonrad Zieliński
Konrad Zieliński
SJStanisław Jurkowski
Stanisław Jurkowski
Background: Digital technologies and 3D printing have transformed implant dentistry, enabling improved precision in implant placement through static and dynamic computer-assisted approaches. Ensuring accurate implant positioning is essential for long-term success, particularly in anatomically demanding or esthetic regions. Objective: To evaluate the accuracy of 3D-printed surgical guides and compare their performance with dynamic navigation, robotic systems, and freehand implant placement techniques. Materials and Methods: A structured narrative review was conducted using the PubMed database (up to November 2025). A total of 44 records were identified, of which 19 studies met the inclusion criteria. These comprised randomized clinical trials, prospective and retrospective studies, in vitro investigations, and systematic or narrative reviews. Data extraction focused on linear and angular deviations, clinical outcomes, guide design, printing technology, and planning protocols. Results: Across included studies, 3D-printed guides consistently demonstrated high accuracy, with mean platform deviations of approximately 0.2–1 mm, apical deviations of 0.5–1.6 mm, and angular deviations of 1–3°. Clinical findings mirrored in vitro results. Dynamic navigation achieved comparable accuracy, while robotic systems showed even lower angular deviations (<1.6°). Guide stability, printing technology, and imaging protocol significantly influenced outcomes. Conclusion: 3D-printed surgical guides provide predictable, clinically acceptable precision and enhance the safety and efficiency of implant placement. Dynamic and robotic systems offer promising complementary technologies. Further long-term clinical trials are needed to establish their definitive clinical impact.

23 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MMMichał Mazurek
Michał Mazurek
KGKarolina Ganczar
Karolina Ganczar
MZMikołaj Zalewski
Mikołaj Zalewski
MRMarianna Rudzińska
Marianna Rudzińska
SJStanisław Jurkowski
Stanisław Jurkowski
KBKarolina Buć
Karolina Buć
Benign breast lesions comprise a wide spectrum of non-malignant proliferative, cystic, papillary, fibrotic, and inflammatory conditions that constitute the majority of abnormalities detected in breast imaging. Although inherently non-malignant, many of these lesions closely mimic malignancy on mammography, ultrasound, and MRI, presenting persistent diagnostic challenges in clinical practice. This review provides an integrated overview of the epidemiology, imaging characteristics, histopathologic features, and clinical management of the most common benign breast entities, including fibroadenoma, breast cyst, intraductal papilloma, sclerosing adenosis, fat necrosis, and radial scar. Each entity is discussed with emphasis on distinguishing imaging findings, risk associations, and the importance of radiologic-pathologic concordance in guiding management. While lesions such as fibroadenomas and simple cysts typically demonstrate benign imaging profiles and require minimal intervention, other lesions-including papillomas, radial scars, and sclerosing adenosis-are more complex due to their variable appearance and association with increased breast cancer risk. Conditions like fat necrosis and radial scars exemplify benign mimickers of malignancy, frequently resulting in false-positive imaging assessments and necessitating tissue sampling. A dedicated section highlights diagnostic pitfalls across imaging modalities and pathology, underscoring the value of multimodal assessment and careful evaluation of discordant findings. Collectively, this review reinforces the need for an individualized, correlation-driven diagnostic approach to ensure appropriate management, minimize unnecessary procedures, and maintain high diagnostic accuracy in contemporary breast imaging.

30 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MRMarianna Rudzińska
Marianna Rudzińska
MZMikołaj Zalewski
Mikołaj Zalewski
KZKonrad Zieliński
Konrad Zieliński
SJStanisław Jurkowski
Stanisław Jurkowski
ŁKŁukasz Krzystek
Łukasz Krzystek
JJJagoda Józefczyk
Jagoda Józefczyk
Background: The evolution of surgical practice has seen a significant shift from open surgery toward minimally invasive techniques. Conventional Laparoscopic Surgery (CLS) replaced many open procedures. It offers benefits like reduced length of hospital stay and lower infection rates. Subsequent technological advancement introduced Robot-Assisted Surgery (RAS), notably utilizing systems like Da Vinci. RAS was specifically developed to overcome the inherent technical limitations of CLS. These include restricted instrument range and two-dimensional viewing. The continuous integration of advanced technologies, including Artificial Intelligence (AI) and Machine Learning (ML), is defining the future role of technology in surgery. This moves towards enhanced precision and autonomous systems. Objective: This analysis aims to synthesize the current evidence comparing Robot-Assisted Surgery (RAS) to Conventional Laparoscopic Surgery (CLS) and open surgery. It focuses on key parameters including clinical outcomes (safety and efficacy), socio-economic costs, and surgeon ergonomics. Methods: This is a narrative synthesis drawing upon recent systematic reviews, meta-analyses, and comparative retrospective studies found in the literature. These primarily compared RAS and CLS across various surgical disciplines. Examples include colorectal surgery, gynecological surgery (e.g., hysterectomy), and nephrectomy. Results: RAS systems offer inherent technical advantages such as superior visualization (3D, high-definition) and enhanced precision due to tremor filtration, motion scaling, and articulated instruments. The learning curve for performing complex technical tasks, such as intracorporeal suturing, is significantly shorter for novice surgeons utilizing robotic assistance compared to those performing CLS. In clinical practice, RAS generally yields comparable results to CLS in terms of major postoperative complications, mortality, and readmission rates. However, RAS is consistently associated with a significantly lower conversion rate to open surgery and a shorter length of hospital stay across nearly all analyzed surgical categories. Conversely, RAS procedures are typically associated with significantly higher total costs (including hospitalization and operative costs) compared to CLS. Furthermore, the operative time for RAS is generally longer than for CLS. In terms of ergonomics, studies indicate that RAS offers better outcomes for surgeons. This results in reduced physical demand and muscle strain compared to the conventional laparoscopic technique. Conclusion: Robotic surgery shows considerable potential for the future, especially for complex surgical procedures performed in anatomically challenging areas. This is primarily due to its ability to minimize conversion rates and shorten hospital stays. Nonetheless, given the substantial associated costs, cost optimization and reduction in equipment and procedure expenses are critical steps. These are required to ensure widespread accessibility and justify its overall value compared to the cost-effective laparoscopic approach.

30 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JJJagoda Józefczyk
Jagoda Józefczyk
PBPaweł Buć
Paweł Buć
KBKarolina Buć
Karolina Buć
ŁKŁukasz Krzystek
Łukasz Krzystek
KZKonrad Zieliński
Konrad Zieliński
SJStanisław Jurkowski
Stanisław Jurkowski
Type 2 diabetes mellitus (T2DM) remains a major global health burden, driven by insulin resistance, progressive β-cell dysfunction, chronic inflammation, and metabolic dysregulation. Conventional pharmacotherapies often exhibit limited bioavailability, suboptimal targeting, and insufficient capacity to modulate the underlying mechanisms of disease progression. In recent years, nanotechnology has emerged as a highly promising therapeutic strategy capable of addressing these limitations. This narrative review evaluates current advancements in nanotechnology-based interventions for T2DM, with a focus on nanocarrier design, mechanisms of action, and translational potential. Across the analyzed studies, diverse nanoplatforms—including polymeric nanoparticles, lipid-based nanocarriers, nanomicelles, PLGA systems, bilosomes, gold nanoparticles, and stimulus-responsive Pickering emulsions—demonstrated significant improvements in drug stability, controlled release, intestinal absorption, and metabolic outcomes. Notably, nanocarriers enhanced the therapeutic performance of incretin-based agents (GLP-1, liraglutide), enabled progress toward oral insulin delivery, and increased the bioavailability of conventional antidiabetic drugs such as metformin and glimepiride. Additionally, nanostructures encapsulating natural bioactive compounds (e.g., naringenin, oleanolic acid, resveratrol) exhibited potent antioxidant, anti-inflammatory, and metabolic benefits. Several innovative systems further demonstrated glucose- or pH-responsive behavior, enabling intelligent and targeted drug release. Preclinical evidence consistently showed improved glycemic control, enhanced β-cell protection, reduced inflammatory markers, and favorable effects on lipid metabolism and body weight. However, the predominance of in vitro and in vivo animal studies underscores the need for robust clinical investigations to evaluate long-term safety, pharmacokinetics, and real-world therapeutic efficacy. Overall, nanotechnology offers a promising avenue for the development of more effective, precise, and multidimensional treatments for T2DM. Continued translational and clinical research is essential to support its integration into future diabetes management.

13 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
SJStanisław Jurkowski
Stanisław Jurkowski
KZKonrad Zieliński
Konrad Zieliński
JJJagoda Józefczyk
Jagoda Józefczyk
KGKarolina Ganczar
Karolina Ganczar
PBPaweł Buć
Paweł Buć
MMMichał Mazurek
Michał Mazurek
Background: Benign prostatic hyperplasia (BPH) remains one of the most common causes of lower urinary tract symptoms in aging men. Surgical intervention is required when medical therapy becomes insufficient, and recent technological advancements have introduced several minimally invasive alternatives to traditional transurethral resection of the prostate (TURP). This review provides a contemporary comparison of TURP, holmium laser enucleation (HoLEP), thulium laser enucleation (ThuLEP), and Aquablation. Methods: A narrative review was conducted using a structured PubMed search with the query: "Benign Prostatic Hyperplasia" AND (TURP OR HoLEP OR ThuLEP OR Aquablation) AND "minimally invasive surgery". A total of 43 studies published between 1993 and 2025 were screened, and 15 met the inclusion criteria. Data on perioperative outcomes, functional results, complications, and retreatment rates were extracted and synthesized qualitatively. Results: TURP remains an effective reference procedure but presents higher bleeding risk, longer catheterization, and increased rates of sexual dysfunction compared with modern alternatives. HoLEP demonstrated superior symptom improvement, reduced blood loss, and durable efficacy across all prostate sizes. ThuLEP showed comparable functional outcomes and strong hemostatic performance. Aquablation offered robot-assisted precision with reduced thermal injury and favorable preservation of ejaculatory function, particularly in larger prostates. Each technique demonstrated clinically meaningful improvements in LUTS and urinary flow, with minimally invasive modalities generally offering more favorable perioperative profiles. Conclusions: Contemporary evidence supports the growing use of HoLEP, ThuLEP, and Aquablation as effective and often superior alternatives to TURP. Surgical selection should be individualized based on prostate size, patient comorbidities, sexual function priorities, and surgeon expertise. Further high-quality comparative studies are warranted.

30 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KZKonrad Zieliński
Konrad Zieliński
SJStanisław Jurkowski
Stanisław Jurkowski
MZMikołaj Zalewski
Mikołaj Zalewski
MRMarianna Rudzińska
Marianna Rudzińska
KGKarolina Ganczar
Karolina Ganczar
ŁKŁukasz Krzystek
Łukasz Krzystek
Background: Inflammatory bowel disease (IBD), principally comprising ulcerative colitis (UC) and Crohn’s disease (CD), represents a growing global health burden characterized by chronic, relapsing inflammation of the gastrointestinal tract. The pathogenesis is multifactorial, involving genetic susceptibility, gut microbiota dysbiosis, and a dysregulated immune response. Current pharmacological strategies, including aminosalicylates, corticosteroids, immunomodulators, and biologics, are effective but often limited by non-specific distribution, low local bioavailability due to rapid gastrointestinal clearance, and severe systemic adverse effects such as immunosuppression and hepatotoxicity. Consequently, there is an urgent clinical need for novel therapeutic approaches that can deliver drugs precisely to the inflamed mucosa while minimizing systemic exposure. Nanotechnology has emerged as a transformative strategy to address these challenges by enabling targeted, controlled, and efficient drug delivery. Objective: This narrative review aims to provide a comprehensive evaluation of the state-of-the-art nanotechnology-based drug delivery systems (DDSs) for IBD treatment. It critically analyzes specific targeting mechanisms-including passive accumulation via the epithelial enhanced permeability and retention (eEPR) effect, active receptor targeting, and stimuli-responsive release-and assesses the therapeutic efficacy of novel nanocarriers loading a wide range of bioactive agents. Materials and Methods: A structured narrative review was conducted based on an extensive analysis of scientific literature published between 2015 and 2025. The review included original in vitro and in vivo studies focusing on organic (polymeric, lipid, hydrogel), inorganic (metallic, silica), and biomimetic nanocarriers. Data extraction prioritized physicochemical properties (size, charge), specific targeting ligands (e.g., hyaluronic acid, mannose, folate), and the modulation of key inflammatory pathways (NF-κB, ROS scavenging, cytokine production). Results: The analysis revealed that nanoparticle-based systems significantly enhance drug accumulation in inflamed colonic tissues compared to free drugs. Passive targeting strategies leveraging the eEPR effect and charge-dependent mucoadhesion demonstrated improved retention times. Active targeting utilizing ligands for CD44 (hyaluronic acid), mannose receptors (CD206), and transferrin receptors facilitated superior cellular uptake by activated macrophages and epithelial cells. Innovative stimuli-responsive formulations, such as pH-sensitive liposomes, ROS-responsive nanozymes (e.g., cerium oxide, manganese-polyphenol), and enzyme-degradable polysaccharide carriers, provided precise release profiles triggered by the pathological microenvironment. These systems effectively restored the intestinal barrier, significantly reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and mitigated oxidative stress in murine colitis models. Furthermore, natural compounds like curcumin and resveratrol showed dramatically improved bioavailability and therapeutic potential when encapsulated in nanocarriers. Conclusion: Nanotechnology-based DDSs represent a promising frontier in IBD therapy, offering a paradigm shift from systemic immunosuppression to precision local treatment. By maximizing local drug concentration and minimizing off-target effects, these systems address the fundamental limitations of current pharmacotherapy. While preclinical results are highly encouraging, further research focusing on long-term safety, scalable manufacturing, and rigorous clinical validation is essential to translate these innovations into standard clinical practice.